BioArctic AB (publ) (BIOA-B) - Net Assets

Latest as of September 2025: Skr1.97 Billion SEK ≈ $211.93 Million USD

Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has net assets worth Skr1.97 Billion SEK (≈ $211.93 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.60 Billion ≈ $279.92 Million USD) and total liabilities (Skr631.81 Million ≈ $67.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIOA-B asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr1.97 Billion
% of Total Assets 75.71%
Annual Growth Rate 26.44%
5-Year Change -1.36%
10-Year Change N/A
Growth Volatility 298.52

BioArctic AB (publ) - Net Assets Trend (2015–2024)

This chart illustrates how BioArctic AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore BioArctic AB (publ) balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for BioArctic AB (publ) (2015–2024)

The table below shows the annual net assets of BioArctic AB (publ) from 2015 to 2024. For live valuation and market cap data, see BIOA-B market cap.

Year Net Assets Change
2024-12-31 Skr894.94 Million
≈ $96.31 Million		 -14.49%
2023-12-31 Skr1.05 Billion
≈ $112.63 Million		 +33.11%
2022-12-31 Skr786.24 Million
≈ $84.61 Million		 -0.31%
2021-12-31 Skr788.68 Million
≈ $84.87 Million		 -13.07%
2020-12-31 Skr907.30 Million
≈ $97.64 Million		 -6.90%
2019-12-31 Skr974.50 Million
≈ $104.87 Million		 -4.25%
2018-12-31 Skr1.02 Billion
≈ $109.52 Million		 +59.99%
2017-12-31 Skr636.13 Million
≈ $68.46 Million		 +946.96%
2016-12-31 Skr60.76 Million
≈ $6.54 Million		 -43.89%
2015-12-31 Skr108.28 Million
≈ $11.65 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to BioArctic AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 184.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Skr305.11 Million 34.09%
Common Stock Skr1.77 Million 0.20%
Other Comprehensive Income Skr958.00K 0.11%
Other Components Skr587.10 Million 65.60%
Total Equity Skr894.94 Million 100.00%

BioArctic AB (publ) Competitors by Market Cap

The table below lists competitors of BioArctic AB (publ) ranked by their market capitalization.

Company Market Cap
Konecranes Plc
HE:KCR
 $2.59 Billion
GOLDEN AGRI-RES ADR/100
F:4G3
 $2.59 Billion
Zhuhai Bojay Electronics Co Ltd
SHE:002975
 $2.59 Billion
ViTrox Corporation Bhd
KLSE:0097
 $2.59 Billion
Brightstar Lottery PLC
NYSE:BRSL
 $2.59 Billion
Energisa S.A
SA:ENGI3
 $2.58 Billion
Hyosung Corp
KO:004800
 $2.58 Billion
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
 $2.58 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BioArctic AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,046,575,000 to 894,942,000, a change of -151,633,000 (-14.5%).
  • Net loss of 177,079,000 reduced equity.
  • Share repurchases of 6,016,000 reduced equity.
  • New share issuances of 6,016,000 increased equity.
  • Other factors increased equity by 25,446,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-177.08 Million -19.79%
Share Repurchases Skr6.02 Million -0.67%
Share Issuances Skr6.02 Million +0.67%
Other Changes Skr25.45 Million +2.84%
Total Change Skr- -14.49%

Book Value vs Market Value Analysis

This analysis compares BioArctic AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 32.03x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 263.33x to 32.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 Skr1.23 Skr323.80 x
2016-12-31 Skr0.69 Skr323.80 x
2017-12-31 Skr7.22 Skr323.80 x
2018-12-31 Skr11.56 Skr323.80 x
2019-12-31 Skr11.07 Skr323.80 x
2020-12-31 Skr10.30 Skr323.80 x
2021-12-31 Skr8.96 Skr323.80 x
2022-12-31 Skr8.93 Skr323.80 x
2023-12-31 Skr11.83 Skr323.80 x
2024-12-31 Skr10.11 Skr323.80 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BioArctic AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -19.79%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -68.81%
  • • Asset Turnover: 0.23x
  • • Equity Multiplier: 1.24x
  • Recent ROE (-19.79%) is below the historical average (12.51%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 3.43% 8.92% 0.32x 1.21x Skr-7.12 Million
2016 94.77% 54.52% 0.15x 11.65x Skr51.50 Million
2017 2.38% 10.77% 0.12x 1.79x Skr-48.46 Million
2018 37.50% 53.45% 0.51x 1.37x Skr279.83 Million
2019 9.08% 31.40% 0.24x 1.21x Skr-8.98 Million
2020 -7.55% -109.90% 0.06x 1.16x Skr-159.25 Million
2021 -15.19% -517.54% 0.03x 1.14x Skr-198.66 Million
2022 -1.42% -4.90% 0.27x 1.09x Skr-89.80 Million
2023 21.90% 37.22% 0.52x 1.13x Skr124.59 Million
2024 -19.79% -68.81% 0.23x 1.24x Skr-266.57 Million

Industry Comparison

This section compares BioArctic AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $138,688,994
  • Average return on equity (ROE) among peers: -117.28%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BioArctic AB (publ) (BIOA-B) Skr1.97 Billion 3.43% 0.32x $2.59 Billion
2cureX AB (2CUREX) $12.08 Million -269.23% 0.35x $4.90 Million
Ascelia Pharma AB (publ) (ACE) $236.06 Million -41.81% 0.08x $40.96 Million
AcouSort AB (ACOU) $3.88 Million -156.37% 0.27x $8.97 Million
Active Biotech AB (ACTI) $339.92 Million -51.49% 1.05x $17.19 Million
Alzinova AB (ALZ) $20.63 Million -16.51% 0.08x $4.97 Million
AlzeCure Pharma (ALZCUR) $32.97 Million -235.89% 0.38x $18.18 Million
Annexin Pharmaceuticals AB (ANNX) $46.73 Million -111.59% 0.13x $11.24 Million
Alligator Bioscience AB (ATORX) $468.31 Million -32.04% 0.09x $14.33 Million
BioInvent International AB (BINV) $87.62 Million -140.56% 0.37x $155.44 Million

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.59 Billion
Skr24.04 Billion SEK
Market Cap Rank
#5393 Global
#71 in Sweden
Share Price
Skr323.80
Change (1 day)
+1.76%
52-Week Range
Skr172.00 - Skr364.40
All Time High
Skr377.80
Categories
Companies in Sweden Biotechnology
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more